OKYO Pharma’s top execs pile on shares, signaling confidence amid shaky valuation and a looming Phase‑3 eye‑drug breakthrough.

Chief Scientific Officer’s Latest Purchase Signals Confidence in OKYO’s Pipeline

In a recent Form 3 filing, Dr. Patil Rajkumar V., the Chief Scientific Officer of OKYO Pharma Ltd., disclosed the acquisition of a substantial block of the company’s common shares. The transaction, executed on March 18 2026 at the prevailing market price of $1.64, does not represent a new trade but rather a continuation of a long‑standing holding pattern. Dr. Patil’s portfolio now reflects 16,667 shares, a figure that underscores his personal stake in a company that has struggled to sustain its valuation over the past year, as evidenced by a 39.26 % year‑to‑date decline.

What the Move Means for the Shareholder Base

While the trade itself is modest relative to OKYO’s $86 million market cap, it is noteworthy in the context of the company’s broader insider activity. The same week, senior executives—including the CEO and CFO—executed sizeable purchases of common stock, with the CEO buying 15,000 shares and the CFO acquiring 30,201 shares. This coordinated buying by top management suggests a shared belief that the company’s valuation is undervalued, especially given the biotech sector’s volatility and OKYO’s recent 7.9 % weekly gain. For investors, such alignment of interest can be a positive signal that leadership is committed to the long‑term success of the clinical pipeline.

Strategic Implications for OKYO’s Development Roadmap

OKYO is currently advancing a Phase 3 trial for its lead ocular‑pain therapeutic, a program that could unlock significant upside if the drug demonstrates efficacy and safety. The insider purchases, coupled with the company’s focus on inflammatory eye diseases, reinforce the narrative that OKYO is positioning itself to fill a niche therapeutic gap. However, the company’s negative earnings‑per‑share figure (-$6.8) and recent 52‑week low of $1.34 indicate that cash flow remains a concern. Investors should therefore weigh the optimism signaled by insider buying against the need for continued capital to support late‑stage development and potential regulatory hurdles.

Outlook for Investors

For the market, the insider activity on a backdrop of a 7.9 % weekly rise suggests a short‑term rally may be on the horizon, particularly if the upcoming Phase 3 data release is favorable. Yet, the lack of significant new shares issued and the company’s modest liquidity position mean that any upside will largely depend on the success of the clinical program. Long‑term investors may view the current insider purchases as a vote of confidence, but should remain mindful of the broader biotech risk profile and OKYO’s limited revenue streams at this stage.